HMNC Brain Health Announces $50 Million First Closing of Series B Financing
Summary
HMNC Brain Health, a Munich-based clinical-stage neuroscience company, announced the $50 million first closing of its Series B financing, led by MEDICE (a leading European mental health pharmaceutical company) with participation from existing investor The Maschmeyer Group. Proceeds will support Phase 3-readiness activities for Ketabon (KET01), an oral prolonged-release ketamine formulation for treatment-resistant depression, and Nelivabon (BH-200), a biomarker-guided precision therapy for depressive disorders.
Why it matters
This financing represents a convergence of pharmaceutical and neurotechnology approaches to mental health, with MEDICE's participation signaling strategic validation of HMNC's precision psychiatry pipeline. The KET01 program could become the first at-home oral ketamine therapy for depression.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial